FDA adds pembrolizumab-chemo nod for biliary tract cancer; prior RCC, TMB-H actions standNov 10Regulatory decisionbelzutifanMerck & Co., Inc.Updated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
FDA clears two Welireg supplements for Merck's belzutifan, both approved September 24, 2026Sep 24Regulatory decisionbelzutifanMerck & Co., Inc.
JAVELIN Bladder Medley results posted; Merck files separate MK-2010 trial across six tumor typesSep 1Weekly roundup, 2 itemsavelumabbelzutifan
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
Exelixis Q2 2026 results detail zanzalintinib pipeline progress, narrows guidanceAug 5Quarterly updateExelixisMerck & Co., Inc.
Merck posts Q2 loss on Terns charge, raises full-year sales outlookAug 4Quarterly updateMerck & Co., Inc.
Merck completes MK-4082 obesity pill PK study; adds V132 vaccine and belzutifan pediatric trialsJul 17Weekly roundup, 8 itemsbelzutifanDaiichi Sankyo